The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.

A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.

Zhitong FinanceApr 25 23:38 ET

Express News | Sino Biopharmaceutical - Approval for Marketing of Penpulimab Injection by US FDA

ReutersApr 25 00:17 ET

Hong Kong stock announcement for treasure hunting | Aluminum Corporation Of China reported a net profit attributable to shareholders of approximately 3.538 billion yuan in the first quarter, a year-on-year increase of 58.78%.

SANDS CHINA LTD (01928) reported a total net income for the first quarter that decreased by 5.7% year-on-year to 1.7 billion dollars; SINO BIOPHARM (01177): 45 research achievements will be announced at the 2025 ASCO annual meeting.

Zhitong FinanceApr 24 11:00 ET

SINO BIOPHARM (01177.HK): 45 research results will be announced at the 2025 ASCO Annual Meeting (including 12 oral presentations).

On April 24, Gelonghui reported that SINO BIOPHARM (01177.HK) announced that the group will present 45 of its latest research results at the 2025 annual meeting of the American Society of Clinical Oncology (ASCO), including 12 oral presentations and 4 major research abstracts (LBA).

Gelonghui FinanceApr 24 10:52 ET

Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.

① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?

cls.cnApr 24 03:37 ET

Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.

① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?

cls.cnApr 21 23:57 ET